Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a tailored screening schedule beat annual mammograms?

NCT ID NCT02620852

Prevention Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares annual mammograms to a personalized screening schedule based on each woman's breast cancer risk. Participants choose or are assigned to either annual screening or risk-based screening, which uses genetic testing and personal history. The goal is to see if personalized screening reduces false positives and overdiagnosis while still catching cancers early. The study aims to enroll 100,000 women aged 30-74 across the United States.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
risk assessment and genetic testing
What this could lead to
If successful, this could lead to a smarter, personalized breast cancer screening approach that reduces unnecessary biopsies and anxiety.
What could go wrong
This is a large observational study, not a treatment trial. Results may not change current guidelines quickly, and personalized screening might miss some cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2016

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 74 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Female\* 2. Age 30 years to 74 years old\*\* 3. Reside in the United States\*\*\* NOTE\*: As of 2019, we are now enrolling all persons who identify as female, and will capture both their sex at birth and gender identity in the baseline survey. NOTE\*\*: Eligibility from 2016 - October 2023 included ages 40-74 (WISDOM 1.0) and expanded to age 30 in October 2023 (WISDOM 2.0). NOTE\*\*\*: As of 2019, recruitment is available nationwide. Original eligibility was limited to California, North Dakota, South Dakota, Iowa, Minnesota, Alabama, Louisiana, Illinois OR have coverage from a participating health plan. Exclusion Criteria: 1. Prior Breast cancer or ductal carcinoma in situ (DCIS) diagnosis 2. Prior prophylactic bilateral mastectomy 3. Inability to provide consent 4. Non-English or Spanish proficiency (Spanish participation available: June 2019)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma in situ breast neoplasm ductal breast carcinoma in situ

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Breast cancer screening Breast carcinoma in situ

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    9 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Edith Sanford Breast Center

    ACTIVE_NOT_RECRUITING

    Sioux Falls, South Dakota, 57117, United States

  • Louisiana State University

    ACTIVE_NOT_RECRUITING

    New Orleans, Louisiana, 70112, United States

  • TopLine MD Alliance

    RECRUITING

    Miami, Florida, 33173, United States

  • University of Alabama at Birmingham

    RECRUITING

    Birmingham, Alabama, 35294, United States

  • University of California Davis

    RECRUITING

    Sacramento, California, 95817, United States

  • University of California Irvine

    RECRUITING

    Irvine, California, 92618, United States

  • University of California Los Angeles

    RECRUITING

    Los Angeles, California, 90095, United States

  • University of California San Diego

    RECRUITING

    San Diego, California, 92093, United States

    Contact Email: •••••@•••••

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94115, United States

  • University of Chicago

    RECRUITING

    Chicago, Illinois, 60637, United States

  • Weill Cornell Medicine

    RECRUITING

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.